Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study ID
NCT05609903
Status
Completed

Conditions

  • Breast Cancer Metastatic

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study will evaluate the therapeutic efficacy of the association of Atezolizumab plus nabPaclitaxel in a real life context, in order to document any differences both in terms of activity and safety with respect to the knowledge of the association reported in the literature

Key Dates

Start date
Nov 1, 2019
Status verified
Nov 2022
Primary completion
Aug 1, 2020
Completion
May 31, 2022

Study Design

Enrollment
52 participants (actual)

Primary Outcome Measure

Objective responce rate [ Time Frame: 1 year ]

Related Studies